Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA. Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation

Abdullah Katgı

Bülent Ündar

Celal Acar

Fatih Demirkan

Güner Hayri Özsan

İnci Alacacıoğlu

Mehmet Ali Özcan

Ömür Gökmen Sevindik

Özden Pişkin

Şerife Medeni Solmaz

Case Reports in Hematology

PubMed

Directory of Open Access Journals

Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

Sevindik, Omur Gokmen

ÖZCAN, MEHMET ALİ

Acar, Celal

Solmaz, Serife Medeni

Piskin, Ozden

ÜNDAR, BÜLENT

ÖZSAN, GÜNER HAYRİ

ALACACIOĞLU, İNCİ

DEMİRKAN, FATİH

Katgi, Abdullah

Dokuz Eylul University Research Information System

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA. Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation.</jats:p

Crossref

Case ReportRenal and Neurological Response with Eculizumab in a Patientwith Transplant Associated Thrombotic Microangiopathy afterAllogeneic Hematopoietic Progenitor Cell TransplantationÖmür Gökmen Sevindik, Enci AlacacJoLlu, Abdullah KatgJ,Ferife Medeni Solmaz, Celal Acar, Özden PiGkin, Mehmet Ali Özcan,Fatih Demirkan, Bülent Ündar, and Güner Hayri ÖzsanDepartment of Hematology, Dokuz Eylu¨l University, 35340 Izmir, TurkeyCorrespondence should be addressed to O¨mu¨r Go¨kmen Sevindik; omurgok17@hotmail.comReceived 19 September 2014; Revised 30 December 2014; Accepted 30 December 2014Academic Editor: Eduardo Arellano-RodrigoCopyright © 2015 O¨mu¨r Go¨kmen Sevindik et al.This is an open access article distributed under theCreativeCommonsAttributionLicense, which permits unrestricted use, distribution, and reproduction in anymedium, provided the originalwork is properly cited.Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor celltransplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patientwho was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large celllymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurologicaland renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA.Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor celltransplantation.1. IntroductionTransplantation-associated thrombotic microangiopathy(TA-TMA) represents a challenge after allogeneic hemato-poietic progenitor cell transplantation because of diagnosticuncertainties, lack of established treatment, and an overallpoor prognosis [1]. Eculizumab, which is a monoclonalantibody against terminal complement, has been usedsuccessfully in atypical hemolytic and uremic syndrome andTA-TMA associated with solid organ transplantation. Dataabout its efficacy in TA-TMA associated with hematopoieticprogenitor cell transplantation lacks [2].2. Case ReportWe report a 43-year-old male patient who was diagnosed asTA-TMAafter allogeneic progenitor cell transplantation fromHLA matched sibling donor and treated with eculizumab.The patient was diagnosed with stage 4 ALK negativeanaplastic large cell lymphoma after splenectomy due touncontrolled splenic hemorrhage. Considering the aggressivenature of the disease, CHOP regimen initiated immediatelyafter diagnosis and staging procedures. After two cyclesof CHOP regimen, no significant response was achievedand ESHAP regimen initiated. After two cycles of ESHAPregimen, a short term partial response could be achieved andallogeneic progenitor cell transplantation was applied fromHLA matched (10/10) sibling donor of the patient becauseof progressive disease [3]. Cells were collected peripherallyand the amount of reinfused CD34+ cells was 5.3 × 106/kg.Busulfan and cyclophosphamide were used as conditioningand cyclosporine used for the prophylaxis of graft versushost disease. At the 7th day of reinfusion, acinetobactersepsis developed and patient was put on to a broad spectrumof antibiotics. While recovering from acinetobacter sepsis,a rapid neurological and renal deterioration was observed.Patient was stuporous and had a tonic-clonic epilepticseizure; he also had a severe headache and hallucinationsbefore the onset of seizure. Meanwhile, the ldh level wasincreased dramatically up to 3200U/L and schistocytes wereHindawi Publishing CorporationCase Reports in HematologyVolume 2015, Article ID 425410, 4 pageshttp://dx.doi.org/10.1155/2015/4254102 Case Reports in Hematology00.511.522.533.544.55Day of reinf.7th day of reinf.Day 0 of TA-TMA 1 2 31st eculizumab 4 5 6 7 8 9 102nd eculizumab 11 12 13 14 15 16Creatinine (mg/dL)PlasmaexchangeDay of reinf.7th day of reinf.Day 0 of TA-TMA 1 2 31st eculizumab 4 5 6 7 8 9 102nd eculizumab 11 12 13 14 15 16Plasmaexchange050010001500200025003000350040004500LDH (U/L)Day of reinf.7th day of reinf.Day 0 of TA-TMA 1 2 31st eculizumab 4 5 6 7 8 9 102nd eculizumab 11 12 13 14 15 16Plasmaexchange010203040506070Hb (g/dL)Thrombocyte (103/𝜇L)Day of reinf.7th day of reinf.Day 0 of TA-TMA 1 2 31st eculizumab 4 5 6 7 8 9 102nd eculizumab 11 12 13 14 15 16Plasmaexchange0481216 Glasgow coma scale (GCS)Day of reinf.7th day of reinf.Day 0 of TA-TMA 1 2 31st eculizumabday 4 5 6 7 8 9 10eculizumab day 11 12 13 14 15 16Schistocytes ++ ++ ++ ++ ++ ++ ++ + + + ++ + + +Seizure + +Plasmaexchange2nd −−−−−−−−−−− − − − − − − − − − − −Figure 1: Clinical and biological response to eculizumab therapy.The figure shows data indicating neurological and renal improvement afteradministration of monoclonal C5 antibody eculizumab in our case with TA-TMA posthematopoietic progenitor cell transplantation withcentral nervous syprogenitor involvement. LDH levels were decreased dramatically, but thrombocyte count did not improve, possibly relatedto delayed hematopoietic engraftment.detected at the peripheral blood smear (20–30/HPF). Despitebeing hyponormotensive during the period of sepsis, he hadhypertensive episodes with a maximum of 180/100mmHgaccompanying the neurological symptoms. Cranial MRIand lumbar puncture revealed no pathological feature. CSFculture was negative and cytological analysis revealed nomalignant cells. Viral analysis of CSF and blood was negativeregarding CMVand EBV.HisHb level has decreased from 9.5to 7.2 g/dL with an MCV of 96 fL and reticulocyte count of2.49%. Both direct and indirect coombs tests were negativeand haptoglobulin level was slightly decreased below thelower limit of normal. After ruling out an ongoing infectiousdisease, cerebrovascular event, and malignant infiltration ofCNS with lymphoma, patient was diagnosed, as TA-TMA.ADAMTS13 activity was %37 with no detectable inhibitors.All complement levels were in normal range (C3, C4, FactorH, and Factor I). Urinalysis revealed a protein concentrationof 120mg/dL. Calcineurin inhibitor stopped immediatelyafter diagnosis and plasma exchange was initiated. Plasmaexchange was performed on a daily basis with 1.5 plasmavolumes, using FFP as a replacement fluid. Neurologicalstatus got worse and patient was intubated with a Glasgowcoma scale (GCS) score of 4. Hemodialysis was applied dueto worsening renal functions and acidosis. Despite rigorousplasma exchange, no response was achieved and plasmaexchange was stopped after 5 consecutive cycles. Eculizumabtherapy was initiated according to atypical hemolytic anduremic syndrome dosage. With two weekly administrationsof 900mgs of eculizumab, neurological status got graduallybetter and patient was able to achieve a GCS score of 11.Hemodialysis stopped and a normal glomerular filtration ratecould be achieved. Despite recovering renal and neurologicalstatus, platelet count remained below 20000/microL, possiblyrelated to delayed hematopoietic engraftment (Figure 1).Patient was lost with diffuse alveolar hemorrhage at the 12thday of eculizumab with a stable low platelet count, a normalldh level, a normal glomerular filtration rate, a GCS score of11, and fewer schistocytes at peripheral blood smear.3. DiscussionHematopoietic progenitor cell transplantation- (HPCT-)associated TA-TMA is a well-recognized and potentiallysevere complication of HPCT that can lead to a high riskCase Reports in Hematology 3of morbidity and mortality [4]. The incidence of TA-TMAis 10–35% as reported in the largest retrospective reviewsand studies examining renal and other tissues [1]. Jodeleet al. have reported a 39% incidence in 100 consecutivechildren and young adult patients who had hematopoieticprogenitor cell transplantation [5]. The cause of TA-TMAis multifactorial. Risk factors include high-dose chemother-apy, radiation therapy, unrelated donor, HLA mismatch,exposure to calcineurin inhibitors (CNIs), graft-versus-hostdisease, and infections [1, 6–8]. The release of inflammatorycytokines causes microvascular endothelial injury and acti-vates platelets and coagulation factors, leading to thrombosisand fibrin deposition in microvasculature of organs, mostcommonly in the kidney [1]. Recently, Jodele et al. and Laskinet al. have suggested an involvement of the complementdysregulation in the development of TA-TMA [9, 10]. Limitedfeasibility of tissue diagnosis of HPC-associated TA-TMAhasled to the development of noninvasive diagnostic criteria.Cho et al. had validated the previously described criteria andadded “probable TA-TMA” category, which did not requirerenal and neurological findings for the diagnosis of TA-TMA.Validated criteria included (1) lactate dehydrogenase (LDH)elevated above the upper limit of normal for age, (2) de novothrombocytopenia with a platelet count <50 × 109/L or a≥50% decrease in the platelet count, (3) de novo anemia witha hemoglobin below the lower limit of normal or anemiarequiring transfusion support, (4) microangiopathic changesdefined as the presence of schistocytes in the peripheralblood or histologic evidence of microangiopathy on a tissuespecimen, and (5) absence of coagulopathy and a negativeCoombs test [6]. Plasma ADAMTS13 activity should bemeasured to rule out a possible diagnosis of TTP, eventhough TTP is very rare after HPCT [1, 11]. TA-TMA usuallydevelops around day +60, but early (day +4) and late (2 years)episodes have been described. TA-TMA has been shown tobe associated with a high mortality rate of up to 100% witha median of 75% [1, 4]. Over the last 30 years, several phar-macological and nonpharmacological treatment modalitiesfor managing TA-TMA have been reported, but there is apaucity of data supporting an optimal treatment strategy.The most effective measure is to stop CNI immediately (nodose reduction) by changing GVHD prophylaxis/treatmentto another drug (corticosteroids, mycophenolate). Plasmaexchange usually offers a poor response (median: 35%; range:20–80%) probably because TMA is not associated with anabsence or severe reduction of plasma ADAMTS13 activityand has a high associated mortality (80%). Some authorshave reported successful results with defibrotide, rituximab,daclizumab, and basiliximab therapies [12]. Mulay et al. havereported 24% clinical improvement rate with PE in 33 TA-TMApatients [13].There is only one case defining the efficacyof eculizumab in an adult patient with postallogeneic pro-genitor cell transplantationwhich have developed thromboticmicroangiopathy at the 3rd month of reinfusion. Within 48hours of administering first dose of eculizumab, neurologicalsymptoms and laboratory variables improved dramatically.His neurological status normalized after 2 weeks, and TMAcompletely resolved 3 months later [14]. In a case series ofsix pediatric HPCT recipients who developed TA-TMA, 67%complete remission were achieved with eculizumab, all ofwhom achieved complete blockade of complement activity[15]. To our knowledge, our case is the first in the literaturedefining the efficacy of eculizumab at thrombotic microan-giopathy which developed rapidly after reinfusion. Rapidneurological and renal recovery achieved after eculizumabcould support a possible relationship between complementactivation and TA-TMA. Eculizumab should be a reasonabletreatment approach in patients with TA-TMA after allogeneichematopoietic progenitor cell transplantation.Conflict of InterestsThe authors declare that there is no conflict of interestsregarding the publication of this paper.References[1] B. L. Laskin, J. Goebel, S.M.Davies, and S. Jodele, “Small vessels,big trouble in the kidneys and beyond: hematopoietic stemcell transplantation-associated thrombotic microangiopathy,”Blood, vol. 118, no. 6, pp. 1452–1462, 2011.[2] E. Kansu, “Thrombosis in stem cell transplantation,” Hematol-ogy, vol. 17, supplement 1, pp. S159–S162, 2012.[3] A. J. Ferreri, S. Govi, S. A. Pileri, and K. J. Savage, “Anaplasticlarge cell lymphoma, ALK-negative,” Critical Reviews in Oncol-ogy/Hematology, vol. 85, no. 2, pp. 206–215, 2013.[4] J. N. George, X. Li, J. R. McMinn, D. R. Terrell, S. K. Vesely, andG. B. Selby, “Thrombotic thrombocytopenic purpura-hemolyticuremic syndrome following allogeneic HPC transplantation: adiagnostic dilemma,” Transfusion, vol. 44, no. 2, pp. 294–304,2004.[5] S. Jodele, S. M. Davies, A. Lane et al., “Diagnostic and riskcriteria for HSCT-associated thrombotic microangiopathy: astudy in children and young adults,” Blood, vol. 124, no. 4, pp.645–653, 2014.[6] B.-S. Cho, S.-A. Yahng, S.-E. Lee et al., “Validation of recentlyproposed consensus criteria for thrombotic microangiopathyafter allogeneic hematopoietic progenitor-cell transplantation,”Transplantation, vol. 90, no. 8, pp. 918–926, 2010.[7] A. S. Daly,W. S. Hasegawa, J. H. Lipton, H. A.Messner, and T. L.Kiss, “Transplantation-associated thrombotic microangiopathyis associated with transplantation from unrelated donors, acutegraft-versus-host disease and venoocclusive disease of the liver,”Transfusion and Apheresis Science, vol. 27, no. 1, pp. 3–12, 2002.[8] M. T. Martinez, C. Bucher, G. Stussi et al., “Transplant-associated microangiopathy (TAM) in recipients of allogeneichematopoietic stem cell transplants,” Bone Marrow Transplan-tation, vol. 36, no. 11, pp. 993–1000, 2005.[9] S. Jodele, C. Licht, J. Goebel et al., “Abnormalities in the alter-native pathway of complement in children with hematopoieticstem cell transplant-associated thrombotic microangiopathy,”Blood, vol. 122, no. 12, pp. 2003–2007, 2013.[10] B. L. Laskin, J. Maisel, J. Goebel et al., “Renal arteriolarC4d deposition: a novel characteristic of hematopoietic stemcell transplantation-associated thrombotic microangiopathy,”Transplantation, vol. 96, no. 2, pp. 217–223, 2013.[11] E. D. Batts and H. M. Lazarus, “Diagnosis and treatment oftransplantation-associated thrombotic microangiopathy: real4 Case Reports in Hematologyprogress or are we still waiting?” Bone Marrow Transplantation,vol. 40, no. 8, pp. 709–719, 2007.[12] Hematopoietic Progenitor Cell Transplantation, The EBMTHandbook, 6th edition, 2012.[13] S. Mulay, J. D. Kreuter, S. C. Bryant et al., “Outcomes of plasmaexchange in patients with transplant-associated thromboticmicroangiopathy based on time of presentation since trans-plant,” Journal of Clinical Apheresis, 2014.[14] R. P. de Latour, A. Xhaard, V. Fremeaux-Bacchi et al., “Suc-cessful use of eculizumab in a patient with post-transplantthrombotic microangiopathy,” British Journal of Haematology,vol. 161, no. 2, pp. 279–280, 2013.[15] S. Jodele, J. J. Bleesing, P. A. Mehta et al., “Successful earlyintervention for hyperacute transplant-associated thromboticmicroangiopathy following pediatric hematopoietic stem celltransplantation,” Pediatric Transplantation, vol. 16, no. 2, pp.E39–E42, 2012.Submit your manuscripts athttp://www.hindawi.comStem CellsInternationalHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014MEDIATORSINFLAMMATIONofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Behavioural NeurologyEndocrinologyInternational Journal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Disease MarkersHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014BioMed Research InternationalOncologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Oxidative Medicine and Cellular LongevityHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014PPAR ResearchThe Scientific World JournalHindawi Publishing Corporation http://www.hindawi.com Volume 2014Immunology ResearchHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Journal ofObesityJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014 Computational and  Mathematical Methods in MedicineOphthalmologyJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Diabetes ResearchJournal ofHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Hindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Research and TreatmentAIDSHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Gastroenterology Research and PracticeHindawi Publishing Corporationhttp://www.hindawi.com Volume 2014Parkinson’s DiseaseEvidence-Based Complementary and Alternative MedicineVolume 2014Hindawi Publishing Corporationhttp://www.hindawi.com

https://creativecommons.org/licenses/by/3.0/

Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals

Dokuz Eylul University Research Information System

Crossref